Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S ...

By Padmanabhan Ananthan and Sriparna Roy Feb 9 (Reuters) - Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in ...

Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back ...

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Eli Lilly ( LLY 1.41%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...

It's the latest in a string of science-focused deals that the pharmaceutical giant has made over the past 12 months as its ...